Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.

Journal of the American College of Cardiology - 12 Aug 2014

Lindman Brian R, Dávila-Román Victor G, Mann Douglas L, McNulty Steven, Semigran Marc J, Lewis Gregory D, de las Fuentes Lisa, Joseph Susan M, Vader Justin, Hernandez Adrian F, Redfield Margaret M

Abstract excerpt

BACKGROUND: The RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) study was a multicenter, randomized trial of sildenafil versus placebo in heart failure with preserved ejection fraction (HFpEF) with rigorous entry criteria and extensive phenotypic characterization of participants. OBJECTIVES: The aim of this study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus

Share to Heart Failure

Share to Piperazines

Share to Purines

Share to Stroke Volume

Share to Sulfones

Source

Open in PubMed Open full text

Identifiers

PMID: 25104521
DOI: 10.1016/j.jacc.2014.05.030
PMCID: PMC4133145

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.PMID 25104521Read ↗

Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.Semantic proximity Read ↗

WATCH-DM risk score predicts the prognosis of diabetic phenotype patients with heart failure and preserved ejection fraction.Semantic proximity Read ↗

HFpEF as the Predominant and Underrecognized Heart Failure Phenotype in Type 2 Diabetes: Evidence from the DIABET-IC StudySemantic proximity Read ↗

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.Semantic proximity Read ↗

Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

How Diabetes and Heart Failure Modulate Each Other and Condition Management.Semantic proximity Read ↗

The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathySemantic proximity Read ↗

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Semantic proximity Read ↗

Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.Semantic proximity Read ↗

Molecular Dysfunction and Phenotypic Derangement in Diabetic CardiomyopathySemantic proximity Read ↗

Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches.Semantic proximity Read ↗

Towards a phenotype profiling of the patients with heart failure and preserved ejection fractionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.